Advanced or Metastatic Cholangiocarcinoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035
- Published Date : October 16, 2025
- Updated On : April 13, 2026
- Pages : 154
Advanced or Metastatic Cholangiocarcinoma Market Outlook
Thelansis’s “Advanced or Metastatic Cholangiocarcinoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced or Metastatic Cholangiocarcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Advanced or Metastatic Cholangiocarcinoma Overview
Advanced or metastatic cholangiocarcinoma (CCA) is a rare, aggressive malignancy arising from bile duct epithelial cells, classified anatomically as intrahepatic, perihilar, or distal subtypes, each carrying distinct molecular profiles, surgical considerations, and therapeutic implications. Diagnosed predominantly at advanced stages due to insidious onset, patients present with jaundice, abdominal pain, weight loss, and pruritus, with metastatic dissemination occurring most frequently to liver, lung, peritoneum, and lymph nodes. Comprehensive next-generation sequencing at diagnosis is mandatory, identifying actionable alterations including FGFR2 fusions, IDH1 mutations, HER2 amplifications, BRAF V600E mutations, NTRK fusions, and MSI-H status, each directing distinct targeted therapeutic strategies. Durvalumab combined with gemcitabine-cisplatin, established through the landmark TOPAZ-1 trial, constitutes the current frontline standard of care, superseding chemotherapy alone. Pemigatinib and futibatinib are approved FGFR2 inhibitors addressing fusion-positive disease, while ivosidenib targets IDH1-mutated cholangiocarcinoma in previously treated patients. HER2-amplified disease responds to trastuzumab-based combinations, and NTRK fusion-positive disease benefits from larotrectinib or entrectinib. BRAF V600E mutations are addressed with dabrafenib-trametinib. MSI-H tumours benefit from pembrolizumab immunotherapy. Emerging KRAS G12C and G12D targeted approaches represent active investigational priorities. Locoregional therapies including hepatic arterial infusion and ablative approaches retain utility in selected intrahepatic disease. Prognosis remains poor overall; multidisciplinary tumour board evaluation, clinical trial enrolment, and early palliative integration are indispensable to patient-centred care.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2025–2035)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
Advanced or Metastatic Cholangiocarcinoma Market Outlook
Thelansis’s “Advanced or Metastatic Cholangiocarcinoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced or Metastatic Cholangiocarcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Advanced or Metastatic Cholangiocarcinoma Overview
Advanced or metastatic cholangiocarcinoma (CCA) is a rare, aggressive malignancy arising from bile duct epithelial cells, classified anatomically as intrahepatic, perihilar, or distal subtypes, each carrying distinct molecular profiles, surgical considerations, and therapeutic implications. Diagnosed predominantly at advanced stages due to insidious onset, patients present with jaundice, abdominal pain, weight loss, and pruritus, with metastatic dissemination occurring most frequently to liver, lung, peritoneum, and lymph nodes. Comprehensive next-generation sequencing at diagnosis is mandatory, identifying actionable alterations including FGFR2 fusions, IDH1 mutations, HER2 amplifications, BRAF V600E mutations, NTRK fusions, and MSI-H status, each directing distinct targeted therapeutic strategies. Durvalumab combined with gemcitabine-cisplatin, established through the landmark TOPAZ-1 trial, constitutes the current frontline standard of care, superseding chemotherapy alone. Pemigatinib and futibatinib are approved FGFR2 inhibitors addressing fusion-positive disease, while ivosidenib targets IDH1-mutated cholangiocarcinoma in previously treated patients. HER2-amplified disease responds to trastuzumab-based combinations, and NTRK fusion-positive disease benefits from larotrectinib or entrectinib. BRAF V600E mutations are addressed with dabrafenib-trametinib. MSI-H tumours benefit from pembrolizumab immunotherapy. Emerging KRAS G12C and G12D targeted approaches represent active investigational priorities. Locoregional therapies including hepatic arterial infusion and ablative approaches retain utility in selected intrahepatic disease. Prognosis remains poor overall; multidisciplinary tumour board evaluation, clinical trial enrolment, and early palliative integration are indispensable to patient-centred care.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2025–2035)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)